Interventional Radiologic Treatment of Hepatocellular Carcinoma
|
|
- Ellen Franklin
- 6 years ago
- Views:
Transcription
1 Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular carcinoma arises in up to 90% of cirrhotic patients, mainly due to chronic viral hepatitis and alcohol abuse. Nearly two-thirds of all patients with hepatocellular carcinoma are diagnosed at advanced stages, thus causing problems with treatment. Regardless of the stage of the disease, interventional radiology offers both curative and palliative treatment options in the management of this disease. Selecting the most appropriate treatment requires an initial staging assessment and detailed clinical and radiologic workup. Treatment allocation is based on liver function, size and number of tumors, macrovascular invasion, and extrahepatic spread of disease. Key words: Chemoembolization, Liver transplantation, Radioembolization, Radiofrequency ablation Introduction Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. Curative treatments include surgical resection and liver transplant. In its earlier stages, surgical treatment (resection or liver transplant) may lead to longer survival, but surgical procedures are reserved for a reduced number of patients because of comorbidities, concomitant complications of liver cirrhosis itself, specific contraindications to liver transplant, and shortages of livers from deceased donors. 1 Locoregional therapies are widely used to From the Department of Interventional Radiology, Baskent University, Ankara, Turkey Acknowledgements: The author has no sources of funding for this study and no conflicts of interest to declare. Corresponding author: Fatih Boyvat, Department of Interventional Radiology, Baskent University, Ankara, Turkey Phone: boyvatf@yahoo.com Experimental and Clinical Transplantation (2017) Suppl 2: treat patients with HCC. There are 3 primary interventional radiologic treatment methods for HCC: (1) percutaneous ablative procedures, (2) chemoembolization, and (3) radioembolization. 2,3 Pretreatment assessment The presence of underlying cirrhosis is an essential prerequisite to a noninvasive diagnosis. In a cirrhotic patient, a liver nodule measuring over 10 mm in diameter exhibiting hypervascularization in the arterial phase followed by washout in the portal or late phase on computed tomography or magnetic resonance imaging is suspected to be HCC. 4 If the findings on the initial study are not typical for HCC, a biopsy should be performed to establish diagnosis. 5 The Barcelona Clinic Liver Cancer (BCLC) classification takes into account cancer characteristics (number and size of nodules, macrovascular invasion, and extrahepatic metastasis), cirrhosisrelated variables (liver function and portal hypertension), and general health status of the patients (performance status) (Figure 1). These parameters allow the 5 distinct HCC stages to be associated with different prognosis and specific treatment recommendations to be identified. 6 These treatments based on disease stage are listed below. Percutaneous ablative procedures Local ablative procedures, which include percu - taneous ethanol injection (PEI), microwave coa - gulation therapy, and radiofrequency ablation (RFA), are liver-directed therapies. Radiofrequency ablation is currently performed widely due to the ease of use, safety, reasonable cost, and applicability to minimally invasive techniques. It is standard therapy for very early and early HCC (stage 0 and stage A of BCLC staging system) in cirrhotic patients who are not suitable for surgical resection or liver transplant. Copyright Başkent University 2017 Printed in Turkey. All Rights Reserved. DOI: /ect.TOND16.L8
2 26 Fatih Boyvat/Experimental and Clinical Transplantation (2017) Suppl 2: Exp Clin Transplant Figure 1. Changes in Composition of Overweight and Obese Patients as a Function of Years From Surgery Comparing Body Mass Index Before Surgery and at Point of Initial Study Contact Before Any Diet or Nutrition Counseling Abbreviations: HCC, hepatocellular carcinoma; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization Transarterial chemoembolization Transarterial chemoembolization (TACE) is recom - mended for intermediate-stage HCC (BCLC stage B); however, this group of patients includes those with a broad spectrum of tumors (encapsulated or infiltrating and unifocal or multifocal) and patients with different degrees of liver function. This explains why survival benefits with this treatment vary among patients with intermediate-stage HCC. Careful patient selection is therefore necessary. Transarterial chemoembolization is appropriate for large nonresectable (> 50 mm) or multinodular HCC lesions without vascular invasion or extrahepatic spread. A subgroup of this treatment is conventional TACE for HCC tissue that does not have associated lymph vessels. These features allow stasis of lipiodol in the sinusoidal or portal vein in or around the HCC lesions. Therapy involving selective infusion into tumor vessels of an anticancer drug/lipiodol mixture and an embolic agent (gelatin sponge) are generally called conventional TACE. Transarterial radioembolization Transarterial radioembolization (TARE) is a 2-step procedure: (1) a preparation/simulation phase and (2) a treatment phase. Transarterial radioembolization is a novel treatment using hepatic intra-arterial infusion of radioactive substances such as β-emitting yttrium Y 90 integral to the glass matrix of microspheres or sodium iodine I 131-labeled lipiodol. Published series have shown comparable median survival rates and toxic effects among patients treated with TACE and TARE. First-line TARE is best indicated both for intermediate-stage patients who have lesions that respond poorly to TACE due to multiple tumors or large tumor burden and for patients with locally advanced disease with solitary tumors and seg - mental or lobar portal vein tumor thrombosis. Transarterial radioembolization is also indicated in patients who are classified beyond Milan criteria for down-staging purposes. Combination of locoregional treatments The combination treatment strategy offers both using transarterial and percutaneous procedures. The occlusion of the hepatic arterial flow supplying the HCC lesion is treated with TACE, increasing the ablation volume. Early-stage disease The survival of patients with early-stage HCC may reach 50% to 70% at 5 years after resection, liver transplant, or percutaneous treatments. 7 Surgical resection is the treatment of choice for noncirrhotic patients with HCC. However, most patients with HCC have underlying cirrhosis; thus, resection is not possible. These patients are at risk for hepatic
3 Fatih Boyvat/Experimental and Clinical Transplantation (2017) Suppl 2: decompensation if they do not have adequate hepatic reserves. It is important to consider both quality and quantity of the future liver remnant (FLR) after resection. In patients with limited fibrosis, the risk of postoperative morbidity is low if FLR exceeds 30%; however, an FLR of 40% is typically required in patients with cirrhosis. 8 In patients with insufficient FLR, portal vein embolization can be a useful way to promote hypertrophy of the unaffected hepatic lobe. 5 Liver transplant not only removes the HCC nodules but also corrects the underlying liver disease. According to Milan criteria, patients are eligible for liver transplant if they have a single HCC < 5 cm in diameter or no more than 3 tumors < 3 cm in diameter. 9 In addition, living-donor liver transplant is an excellent treatment for early HCC because deceased-donor liver transplant is limited because of shortages of grafts. An alternative approach to expanding transplant criteria is downstaging tumors to Milan criteria using TACE, TARE, or percutaneous ablation. 10 Percutaneous ablation Percutaneous ablation is the best alternative for patients with early-stage HCC who are not eligible for resection or transplant procedures. 5 Tumor ablation is achieved by modifying the temperature of neoplastic cells (radiofrequency, microwave, laser, and cryoablation) or by using chemical substances (alcohol, acetic acid). 7 The most common techniques are RFA and PEI. Radiofrequency ablation achieves higher rates of complete tumor ablation than PEI. Recurrence rate is higher with PEI treatment. Radiofrequency ablation significantly improves survival and reduces local recurrence compared with PEI, supporting the use of RFA as first-line treatment in patients with small HCC lesions (< 3 cm) and who have well-preserved hepatic function (Figure 2). Percutaneous ethanol injection should be reserved for cases in which RFA is not technically possible (pericholecystic lesions or lesions near the hepatic hilum). 11 For patients with intermediate-stage HCC, TACE is the standard treatment; however, radioembolization also has a role in treatment. The liver receives blood from the portal vein and hepatic artery at a ratio of 3:1 in the normal liver. Those with HCC receive blood flow through the hepatic artery only and do not depend on portal vein blood flow. Transarterial chemoembolization involves selective delivery of intra-arterial chemotherapy into the tumor, followed Figure 2. Percutaneous Radiofrequency Ablation of HCC Lesion by embolization with a goal of inducing tissue necrosis. Transarterial chemoembolization results in a significantly prolonged 2-year survival of 63% versus 27% with supportive care. 3,12 Superselective TACE for HCC has been shown to result in overall median survival of 3.3 years and 5-year survival rate of 34%. Transarterial chemoembolization has also resulted in higher survival rates in patients with fewer tumor numbers, smaller tumor size, and better liver function. 13 Adverse effects associated with TACE include nausea and vomiting, bone marrow aplasia, renal failure, and the potential for cardiac toxicity. Fever after TACE is usually due to postembolization syndrome, which is reflective of tumor necrosis, acute cytokine release, and systemic exposure to chemotherapeutic agents. The most important contraindications for TACE are the absence of portal flow due to portal vein thrombosis, hepatofugal flow, or portosystemic anastomosis. Patients with Child-Pugh C score, some patients with Child-Pugh B score, patients who are BCLC stage D, and patients with clinical symptoms
4 28 Fatih Boyvat/Experimental and Clinical Transplantation (2017) Suppl 2: Exp Clin Transplant of end-stage cancer should also be excluded, as the ischemic insult can lead to severe and even fatal adverse events. 14 A number of factors have been correlated with effective post-tace response. These include tumor diameter < 5 cm, < 50% replacement of liver by tumor tissue, and unilobar tumor. Other prognostic factors include the alpha-fetoprotein level, differentiation of HCC, number of tumor nodules, portal vein thrombosis, presence of tumor capsule, and degree of lipiodol retention postprocedure. 5,10,15 Drugeluting beads are microspheres that can be loaded with chemotherapeutic agents and used for TACE. Drug-eluting beads produce controlled, sustained release of chemotherapy at decreased peak plasma levels within the systemic circulation (Figure 3). A randomized clinical trial among 212 patients with intermediate-stage HCC found that TACE with drugeluting beads resulted in similar response rates to conventional TACE (27% vs 22% complete response and 25% vs 21% partial response) and similar treatment-related serious adverse effects. 16 Radioembolization Radioembolization is also based on the arterial vascularization of the HCC and involves injection of micron-sized embolic particles with a radioisotope, yttrium Y 90, into the hepatic artery. The intra-arterial radioactive compounds have the ability to deliver high doses of radiation to small target volumes and have a relatively low-toxicity profile. First-line TARE is indicated for intermediate-stage patients who have lesions that respond poorly to TACE due to multiple tumors or a large tumor burden, locally advancedstage patients with solitary tumors, and those with segmental or lobar portal vein tumor thrombosis. 17 Preparatory angiography is necessary before injection of the radioactive particles into the right or left hepatic artery, depending on the site of the tumor. Embolization of the any extrahepatic branch is conducted to avoid dispersion of microspheres to duodenum, stomach, or other nontargeted organs, and then macroaggregates of albumin labeled with technetium Tc 99 are injected. The diffusion of these particles is studied by a single photon emission computed tomography 18 (Figure 4). A single-center prospective cohort study of 291 patients treated with TARE found a complete response rate of 23% and a partial response rate of 34%. Median survival was 17.2 months in patients with Child-Pugh A and 7.7 months in patients with Child-Pugh B. Transarterial radioembolization was better tolerated, with Figure 3. Hypervascular Hepatocellular Carcinoma Lesion in the Right Lobe of Liver A B C D E A and B, Contrast-enhanced computed tomography scan showing hepatocellular carcinoma (HCC) lesion. C and D, Selective angiography showing arterial vascularity. E, Image after use of drug-eluting beads with transarterial chemoembolization showing embolization of HCC lesion.
5 Fatih Boyvat/Experimental and Clinical Transplantation (2017) Suppl 2: Figure 4. Hypervascular Multiple Hepatocellular Carcinoma Lesions in the Right Lobe of Liver A B C D E A, Computed tomography. B and C, Selective angiography and test injection of technetium Tc 99-labeled macroaggregates of albumin. D and E, Single photon emission computed tomography image showing 34% shunt to lungs, not suitable for radioembolization. Figure 5. Computed Tomography Showing Hypervascular Irregular and Large Hepatocellular Carcinoma Lesion (top panels) and Stable Lesion for 2 Years After 1 Session of Chemoembolization and Radioembolization (bottom panels) significantly lower rates of abdominal pain and elevated liver enzymes (Figure 5). Although there was a trend toward higher response rates with TARE than TACE (49% vs 36%; P =.10), median survival was not significantly different (20.5 vs 17.4 mo; P =.23). 19
6 30 Fatih Boyvat/Experimental and Clinical Transplantation (2017) Suppl 2: Exp Clin Transplant Conclusion Hepatocellular carcinoma is currently the leading cause of death in patients with liver cirrhosis. Tumor staging and treatment planning are often based on the Barcelona Clinic Liver Cancer staging system. The mainstays of treatment of HCC are surgery, radiological approach, and systemic drugs. Regardless of the stage of the disease, different interventional radiological treatment options are available for the patients. References 1. Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8(9): Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013;19(24): Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S112-S Aube C, Bouvier A, Lebigot J, Vervueren L, Cartier V, Oberti F. Radiological treatment of HCC: Interventional radiology at the heart of management. Diagn Interv Imaging. 2015;96(6): Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29(3): Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7(9): Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40(3): Farges O, Malassagne B, Flejou JF, Balzan S, Sauvanet A, Belghiti J. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg. 1999;229(2): Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11): Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7(15): Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev. 2012;38(1): Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319): Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012;56(4): Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15(2): , vii-x. 15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2): Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1): Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7(5): Sacco R, Mismas V, Marceglia S, et al. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol. 2015;21(21): Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2): e2.
Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationThe Role of Interventional Radiology (Locoregional
The Role of Interventional Radiology (Locoregional therapies) in HCC Richard Owen MB, MRCP, FRCR Interventional Radiology, Associate Professor University of Alberta Aldo Montana-Loza MD, FRCPC Hepatology
More informationRuolo della interventistica per le secondarietà epatiche e di altre sedi
Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationFeasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients
Original Research Feasibility Study of Transcatheter Arterial Chemoembolization with Epirubicin Drug-eluting Beads for Hepatocellular Carcinoma in Japanese Patients 1) Department of Diagnostic Radiology,
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationTranscatheter hepatic arterial chemoembolization may be considered medically necessary to
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization
More informationRESEARCH ARTICLE. Abstract. Introduction
RESEARCH ARTICLE Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia F Abdul Rahman
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date
MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationResection leads to cure in selected patients with hepatocellular
Overview: Where Does Radiation Therapy Fit in the Spectrum of Liver Cancer Local-Regional Therapies? Laura A. Dawson, MD*, Experience with radiation therapy for the treatment of hepatocellular carcinoma
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationLong-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC)
Original Article Long-term follow-up after conventional transarterial chemoembolization (c-tace) with mitomycin for hepatocellular carcinoma (HCC) Ricardo Yamada, Beatriz Bassaco, Stephen Bracewell, Kirkpatrick
More informationTRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD
UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationDEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE?
DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? Ho Jong Chun, MD., PhD Seoul St. Mary s Hospital, The Catholic University of Korea Why Drug-eluting Beads? Clear Rationale
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHepatocellular carcinoma: Options for diagnosing and managing a deadly disease
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will recognize the risk of hepatocellular carcinoma in patients with cirrhosis, regardless of the cause of the cirrhosis ARVIND R. MURALI, MD Department
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationTransarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.473 Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions MINI-REVIEW Transarterial Therapies
More informationHepatocellular carcinoma (HCC) is the sixth most common
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:604 611 Chemoembolization and Radioembolization for Hepatocellular Carcinoma RIAD SALEM and ROBERT J. LEWANDOWSKI Section of Interventional Radiology, Division
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationHepatocellular carcinoma (HCC) is the most common
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes RIAD SALEM,*,, ROBERT J. LEWANDOWSKI,* MARY F. MULCAHY, AHSUN RIAZ,* ROBERT K.
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationtreatment options for primary liver malignancies and metastatic disease
State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure
More informationUPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*
UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for primary liver cancer Selective internal
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationGut Online First, published on May 5, 2005 as /gut
Gut Online First, published on May 5, 2005 as 10.1136/gut.2005.069237 p53 gene (Gendicine ) and embolization overcame recurrent hepatocellular carcinoma Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. Authors
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationCHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES
CHEMOEMBOLISATION USING IODIZED OIL(LIPIODOL ) BASED TECHNIQUES Peter Huppert Department of Radiology, Neuroradiology and Nuclear Medicine Klinikum Darmstadt ATH Universities of Frankfurt and Heidelberg/Mannhein
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationRecent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma
Current Treatment Paradigms in Hepatocellular Carcinoma Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma Mary Maluccio, MD, MPH 1 ; Anne Covey, MD 2 Hepatocellular carcinoma
More informationTransarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma
DOI:10.22034/APJCP.2017.18.1.189 Combined TACE and MWA or RFA for HCC RESEARCH ARTICLE Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular
More informationRegional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine
Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection
More informationPRIOR AUTHORIZATION Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products.
Medical Coverage Policy Radioembolization for Primary and Metastatic Tumors of the Liver EFFECTIVE DATE: 10 06 2009 POLICY LAST UPDATED: 08 02 2016 OVERVIEW Radioembolization (RE), referred to as selective
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationHamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.
Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE. YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA EFFICACY AND SAFETY OF YTTRIUM-90 RADIO- EMBOLIZATION
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Liver 2013 2014 NAACCR Webinar Series June 5, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationTransarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (ctace)
Med Sci Monit, 2011; 17(4): 189-195 PMID: 21455104 WWW.MEDSCIMONIT.COM Clinical Research Received: 2010.08.04 Accepted: 2010.10.31 Published: 2011.04.01 Transarterial Chemoembolization of Child-A hepatocellular
More informationCorporate Medical Policy
Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors
More informationRadioembolization for the treatment of hepatocellular carcinoma
pissn 2287-2728 eissn 2287-285X Review https://doi.org/10.3350/cmh.2017.0004 Clinical and Molecular Hepatology 2017;23:109-114 Radioembolization for the treatment of hepatocellular carcinoma Hyo-Cheol
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationChemoembolization of Hepatocellular Carcinoma
3 Chemoembolization of Hepatocellular Carcinoma RiccardoLencioni,MD,FSIR,EBIR 1 Pasquale Petruzzi, MD 1 LauraCrocetti,MD,PhD,EBIR 1 1 Division of Diagnostic Imaging and Intervention, Pisa University School
More informationAMSER Case of the Month: June 2018
AMSER Case of the Month: June 2018 64 year old male undergoing evaluation for liver transplant By Timothy Morgan, MS IV Lake Erie College of Osteopathic Medicine Jonathan Potts, MD Interventional Radiology,
More informationWorldwide, hepatocellular carcinoma
Vascular and Interventional Radiology Review Fidelman and Kerlan TACE and 90 Y Radioembolization to Treat HCC Vascular and Interventional Radiology Review FOCUS ON: Nicholas Fidelman 1 Robert K. Kerlan,
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationPost-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma
DOI:10.1111/hpb.12487 HPB ORIGINAL ARTICLE Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma Meredith C. Mason 1,2,
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationMP Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Medical Policy MP 8.01.11 BCBSA Ref. Policy: 8.01.11 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.75 Cryosurgical Ablation of Primary or Metastatic Liver Tumors
More informationSurvival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC
Vascular and Interventional Radiology Original Research Prajapati et al. Doxorubicin Drug-Eluting Beads in TACE of HCC Vascular and Interventional Radiology Original Research Hasmukh J. Prajapati 1 Minzhi
More information